1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer
  4. >>Immuno-oncology

AstraZeneca MYSTIC Read-Out Delay Further Boost To Merck

 
• By Alexandra Shimmings

Overall survival data are now not due until the second half of the year but however they turn out competitor Merck & Co is still expected to dominate the late-stage NSCLC market with Keytruda.

Crystal ball
What does the future hold for MYSTIC? • Source: Shutterstock

AstraZeneca PLC and its global biologics R&D arm, MedImmune, have pushed back the timeline for the final results of the Phase III MYSTIC trial of Imfinzi (durvalumab). The delay is not necessarily more negative for the product's overall prospects in late-stage lung cancer but could provide a small additional boost for rival Merck & Co's Keytruda (pembrolizumab).

The study is event-driven trial and based on current predictions, the final analysis of overall survival (OS) is now expected in the second half

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 
• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Merck Set To Add Perioperative Head-And-Neck Cancer To Keytruda Label

 
• By Joseph Haas

With positive data versus radiation therapy in KEYNOTE-689, Merck & Co. files for approval in perioperative head and neck cancer, adding to additional claim in that cancer type.

Akeso Explains Ivonescimab Prelim OS Data After Investors’ Negative Reactions

 
• By Dexter Jie Yan

Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.

More from Anticancer